Build conviction in the science behind every deal
Surface what will make or break the deal, earlier.
Evaluate assets faster for licensing, acquisition, and investment.
Replace fragmented workflows with a single system.
Today’s fragmented approach can’t keep up
Are you drowning in data but still struggle to build conviction in what will make or break each deal?
More to evaluate.
Same resources.
Teams are expected to assess more assets without additional capacity. Focus is spread thinner.
Diligence that hasn’t scaled.
Decision-making is still slow, manual, and dependent on too many stakeholders.
Missing what will make or break the deal.
Diligence is episodic and evidence is fragmented, making it easy to miss the signals that matter most.
Continuous drug assessment and deal diligence in a single platform
From early-stage programs to late-stage deals, evaluate every asset with a reproducible, evidence based approach.
Screen opportunities with speed and consistency
Connect to all data in one place
Scale dealmaking with faster, more rigorous scientific assessment
Consider the full competitive landscape
Model valuations with confidence
Our Partners
Leading investors supporting the future of life sciences
AI that accelerates your judgment in deal-making
Prudentia brings together data, expert frameworks, and AI to produce outputs grounded in evidence and ready for decision-making.
Scientific diligence frameworks
Apply expert-developed frameworks to evaluate assets consistently
Assess biological mechanism validity and plausibilityEvaluate translational, regulatory, and clinical riskModel pTRS, NPV, and development scenariosAI reasoning, grounded in evidence
Scale scientific reasoning across deals
Models trained for therapeutic area and modalities, across drug development life cycleAI agents that understand drug development risks and opportunitiesEnd-to-end data provenance, with human-in-the-loop validationCentralized evidence
Unify fragmented data sources into a single, connected evidence base
Securely connect to all necessary data sourcesIntegrate public, proprietary, and internal datasetsOrganize all evidence within your company-specific system0% alignment with pharma diligence assessments
Extend your experts' judgment - keeping them in the loop while surfacing signals earlier.
Built by teams with decades of life sciences deal experience
Deep expertise across drug development, clinical strategy, and deal execution. This experience shapes the scientific frameworks behind every Prudentia evaluation.
Meet the teamMeet the team$0B+
Deal value across team experience
0+
Assets evaluated
0+
Drugs brought to market including Keytruda, Celebrex, Chimera, and more
Protected by design
Life sciences dealmaking involves some of the most sensitive data in the industry.
Visit our Trust CenterVisit our Trust Center
Secure Private Infrastructure
Single-tenant deployment with your data siloed and never shared across customers
Granular access controls
SSO integration with granular access controls and permissions
Data protected end-to-end
Encryption at rest and in transit, with complete audit trails
Built-in compliance
Your data is never used to train models, aligned with ISO/IEC 42001:2023
For biotech teams:
See your asset through a partner's lens
Stay ahead of competitor pipelines and deal activity in real time
Identify and connect with the right partners based on real-time deal signals
Position your asset using the same frameworks pharma and investors apply in diligence
Benchmark your asset and time your outreach with confidence